The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter is a key predictor of temozolomide chemosensitivity (2), whereas isocitrate dehydrogenase (IDH) mutations are strongly associated with molecular typing of gliomas and good prognosis (3). Here, IDH1 is linked to central nervous system cancer.